RevMed’s first-in-class pancreatic therapy among fastest CNPV approvals 

Approval of Revolution Medicines’ daraxonrasib for pancreatic ductal adenocarcinoma makes it the first targeted oncology therapy in a new class of RAS(ON) inhibitors and the first new cancer drug to gain FDA’s backing under the commissioner’s national priority review voucher initiative. 

Revolution Medicines Inc. (NASDAQ:RVMD) is launching Rasonque daraxonrasib immediately at a WAC of $39,800 for a 30-day supply...